ClinicalTrials.Veeva

Menu

Cardiovascular Events in Chronic Obstructive Pulmonary Disease Patients Initiating Olodaterol or Other Long-acting beta2 Agonists

Boehringer Ingelheim logo

Boehringer Ingelheim

Status

Completed

Conditions

Pulmonary Disease, Chronic Obstructive

Study type

Observational

Funder types

Industry

Identifiers

NCT03405363
1222.54

Details and patient eligibility

About

Examine the risk of cardiovascular events (cardiac arrhythmia or myocardial ischemia) or all-cause mortality in Chronic Obstructive Pulmonary Disease (COPD) patients who are new users of Olodaterol or other LABAs available for the treatment of COPD.

Full description

Purpose:

Time Perspective:

Enrollment

65,406 patients

Sex

All

Ages

40 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • COPD diagnosis
  • aged 40 years or older (to minimise the likelihood of including individuals who have asthma only)
  • New user of olodaterol or a new user of indacaterol, salmeterol, or formoterol (not in fixed-dose combination with an inhaled corticosteroid) and have no dispensing of any LABA in the 6 months before the index date
  • at least 1 year of enrolment in the electronic database before their first LABA dispensing (defined as the index LABA)
  • Complete data on sex

Exclusion criteria

none

Trial design

65,406 participants in 2 patient groups

new users of Olodaterol
Description:
COPD patients using Olodaterol for the first time
new users of other LABAs
Description:
COPD patients using other long-acting beta2 agonists for the first time

Trial documents
1

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems